
    
      This is a randomized, single -center study conducted in China to compare the tolerability and
      toxicity of different dose of Anlotinib Plus Gefitinib in patients of Advanced GenePositive
      Non-squamous Non-small Cell Lung Cancer.From low dose group up to high dose group, each one
      had 3 patients at least.Primary group received anlotinib 8mg. The dose of Anlotinib would
      increase gradually until MTD. Eligible patients were instructed to take Gefitinib 250mg
      orally daily for three weeks and 8mg/10mg/12mg Anlotinib orally daily on day 1 to 14 of a
      21-day cycle.
    
  